Any feedback?
Literature summary extracted from
- Insights into the selective inhibition of Candida albicans secreted aspartyl protease: a docking analysis study (2002), Bioorg. Med. Chem., 10, 1153-1170.
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 3.4.23.24 | medicine | biochemical target for drug development against clinically important fungal infections | Candida albicans |
Crystallization (Commentary)
| EC Number | Crystallization (Comment) | Organism |
|---|---|---|
| 3.4.23.24 | complexed with inhibitor A-70450 | Candida albicans |
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.23.24 | inhibitor A-70450 | - |
Candida albicans |  |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.23.24 | Candida albicans | P0CS83 | - |
- |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.4.23.24 | SAP | - |
Candida albicans |
| 3.4.23.24 | SAP2X | closely related clinical isolate | Candida albicans |
| 3.4.23.24 | secreted aspartyl protease | - |
Candida albicans |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
